Abstract
Inflammatory diseases such as arthritis are chronic conditions that fail to resolve spontaneously. While the cytokine and cellular pathways triggering arthritis are well defined, those responsible for the resolution of inflammation are incompletely characterized. Here we identified interleukin (IL)-9-producing type 2 innate lymphoid cells (ILC2s) as the mediators of a molecular and cellular pathway that orchestrates the resolution of chronic inflammation. In mice, the absence of IL-9 impaired ILC2 proliferation and activation of regulatory T (Treg) cells, and resulted in chronic arthritis with excessive cartilage destruction and bone loss. In contrast, treatment with IL-9 promoted ILC2-dependent Treg activation and effectively induced resolution of inflammation and protection of bone. Patients with rheumatoid arthritis in remission exhibited high numbers of IL-9+ ILC2s in joints and the circulation. Hence, fostering IL-9-mediated ILC2 activation may offer a novel therapeutic approach inducing resolution of inflammation rather than suppression of inflammatory responses.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nathan, C. & Ding, A. Nonresolving inflammation. Cell 140, 871–882 (2010).
Buckley, C.D., Gilroy, D.W., Serhan, C.N., Stockinger, B. & Tak, P.P. The resolution of inflammation. Nat. Rev. Immunol. 13, 59–66 (2013).
McInnes, I.B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219 (2011).
Kotas, M.E. & Medzhitov, R. Homeostasis, inflammation, and disease susceptibility. Cell 160, 816–827 (2015).
Schett, G. & Gravallese, E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol. 8, 656–664 (2012).
Steinman, L., Merrill, J.T., McInnes, I.B. & Peakman, M. Optimization of current and future therapy for autoimmune diseases. Nat. Med. 18, 59–65 (2012).
Schett, G., Elewaut, D., McInnes, I.B., Dayer, J.M. & Neurath, M.F. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat. Med. 19, 822–824 (2013).
Serhan, C.N., Chiang, N. & Van Dyke, T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349–361 (2008).
Kehoe, O., Cartwright, A., Askari, A., El Haj, A.J. & Middleton, J. Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-induced arthritis. J. Transl. Med. 12, 157 (2014).
Brackertz, D., Mitchell, G.F. & Mackay, I.R. Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum. 20, 841–850 (1977).
Monach, P.A., Mathis, D. & Benoist, C. The K/BxN arthritis model. Curr. Protoc. Immunol. Chapter 15, Unit 15.22 (2008).
Kollias, G. et al. Animal models for arthritis: innovative tools for prevention and treatment. Ann. Rheum. Dis. 70, 1357–1362 (2011).
Ji, H.B. et al. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor–related protein abrogates regulatory T cell suppression. J. Immunol. 172, 5823–5827 (2004).
Stephens, G.L. et al. Engagement of glucocorticoid-induced TNFR family–related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol. 173, 5008–5020 (2004).
Elyaman, W. et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl. Acad. Sci. USA 106, 12885–12890 (2009).
Gerlach, K. et al. TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat. Immunol. 15, 676–686 (2014).
Kaplan, M.H., Hufford, M.M. & Olson, M.R. The development and in vivo function of T helper 9 cells. Nat. Rev. Immunol. 15, 295–307 (2015).
Dardalhon, V. et al. IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cells. Nat. Immunol. 9, 1347–1355 (2008).
Veldhoen, M. et al. Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–producing subset. Nat. Immunol. 9, 1341–1346 (2008).
Ramming, A., Druzd, D., Leipe, J., Schulze-Koops, H. & Skapenko, A. Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development. Blood 119, 4665–4674 (2012).
Lu, L.F. et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442, 997–1002 (2006).
Bannenberg, G.L. et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345–4355 (2005).
Wilhelm, C. et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat. Immunol. 12, 1071–1077 (2011).
Turner, J.E. et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J. Exp. Med. 210, 2951–2965 (2013).
Ciccia, F. et al. Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology 54, 2264–2272 (2015).
Kundu-Raychaudhuri, S., Abria, C. & Raychaudhuri, S.P. IL-9, a local growth factor for synovial T cells in inflammatory arthritis. Cytokine 79, 45–51 (2016).
Chang, H.C. et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat. Immunol. 11, 527–534 (2010).
Nowak, E.C. et al. IL-9 as a mediator of Th17-driven inflammatory disease. J. Exp. Med. 206, 1653–1660 (2009).
Townsend, J.M. et al. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 13, 573–583 (2000).
Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580–1588 (2010).
Prevoo, M.L. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44–48 (1995).
Schauer, C. et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20, 511–517 (2014).
Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258–1266 (1999).
Zhang, G., Budker, V. & Wolff, J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10, 1735–1737 (1999).
McHedlidze, T. et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39, 357–371 (2013).
Lin, N.Y. et al. Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann. Rheum. Dis. 72, 761–768 (2013).
Schneider, C.A., Rasband, W.S. & Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
Thevenaz, P., Ruttimann, U.E. & Unser, M. A pyramid approach to subpixel registration based on intensity. IEEE Trans. Image Process. 7, 27–41 (1998).
Thévenaz, P. & Unser, M. User-friendly semiautomated assembly of accurate image mosaics in microscopy. Microsc. Res. Tech. 70, 135–146 (2007).
Acknowledgements
The authors thank M. Pascual, K. Dreissigacker, R. Kleinlein, M. Comazzi, D. Weidner and B. Happich for excellent technical assistance. We thank U. Appelt and M. Mroz of the Core Unit Cell Sorting and Immunomonitoring Erlangen for cell sorting. This work was supported by the Deutsche Forschungsgemeinschaft (RA 2506/3-1 and RA 2506/4-1 to A.R.; DI 1537/5-1, DI 1537/7-1, DI 1537/8-1, DI 1537/9-1, AK 144/2-1 and DI 1537/11-1 to J.H.W.D.; SCHE 1583/7-1 to G.S.; SPP1468-IMMUNOBONE and CRC1181 to G.S. and J.H.W.D.), the Bundesministerium für Bildung und Forschung (METHARTHROS to G.S. and J.H.W.D.), the Marie Curie project OSTEOIMMUNE (to G.S. and J.H.W.D.), the TEAM project of the European Union and the IMI-funded project RTCure (to G.S.), Else Kröner-Fresenius-Stiftung 2014_A184 (to A.R.), the Wilhelm Sander Foundation (2013.056.1 to J.H.W.D.), the Interdisciplinary Centre for Clinical Research, Erlangen (A64 to J.H.W.D.; J40 to A.R.), the ELAN Fonds of the Universitätsklinikum Erlangen (16-10-05-1 to A.R.), the Career Support Award of Medicine of the Ernst Jung Foundation (to J.H.W.D.), SNF Sinergia CRSII3_154490 (to O.D.), the UK MRC (UI015178805; to A.N.J.M.), the Wellcome Trust (100963/Z/13/Z to A.N.J.M.) and US NIH grant AI057459 (to M.H.K.).
Author information
Authors and Affiliations
Contributions
Design of the study: S.R., G.S., J.H.W.D., A.R. Acquisition of data: S.R., M.L., S. Weber, L.M., A.S., T.W., N.-Y.L., K.D., M.G., A.R. Interpretation of data: S.R., A.B., M.H., A.N.J.M., B.W., M.M.Z., U.F., D.J.V., J.D.C., O.D., F.R., C.P., S. Wirtz, M.F.N., G.S., J.H.W.D., A.R. Support of material: A.B., M.H., M.H.K., B.W., U.F., D.J.V., J.D.C., O.D., F.R., C.P., M.F.N., A.N.J.M., S. Wirtz. Manuscript preparation: S.R., G.S., J.H.W.D., A.R.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–4 and Supplementary Tables 1–4 (PDF 2963 kb)
Rights and permissions
About this article
Cite this article
Rauber, S., Luber, M., Weber, S. et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat Med 23, 938–944 (2017). https://doi.org/10.1038/nm.4373
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4373
This article is cited by
-
GBA1 as a risk gene for osteoporosis in the specific populations and its role in the development of Gaucher disease
Orphanet Journal of Rare Diseases (2024)
-
SLAM-family receptors promote resolution of ILC2-mediated inflammation
Nature Communications (2024)
-
A diversity of novel type-2 innate lymphoid cell subpopulations revealed during tumour expansion
Communications Biology (2024)
-
Locus of (IL-9) control: IL9 epigenetic regulation in cellular function and human disease
Experimental & Molecular Medicine (2024)
-
Tissue microenvironment induces tissue specificity of ILC2
Cell Death Discovery (2024)